 FRAMINGHAM, MA ACCESSWIRE July 28, 2021 Xenetic Biosciences, Inc. NASDAQ:XBIO Xenetic or the Company, a biopharmaceutical company focused on advancing XCARTTM, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the closing of its previously announced private placement with a single healthcare-focused institutional investor for 4,629,630 shares of its common stock or common stock equivalents at a purchase price per share of 2.70, priced at-the-market under Nasdaq rules. The gross proceeds to Xenetic totaled approximately 12.5 million before deducting placement agent fees and other offering expenses. 